Dual GLP-1/gcgr agonists
Intervention1 paper4 findings
Outcomes
3Serious adverse events
no changein humans1RR 0.9High certainty
1 study
Serious adverse events
no changein humans1RR 0.9High certainty
Dual GLP-1/gcgr agonists have no effect on serious adverse events in humans (RR: 0.90).
Reviewin adults with overweight/obesity
Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis · Diabetes, obesity & metabolism · 29 Sep 2026
≥ 5% weight loss
upin humans1RR 4.75High certainty
1 study
≥ 5% weight loss
upin humans1RR 4.75High certainty
Dual GLP-1/gcgr agonists increase ≥ 5% weight loss in humans (RR: 4.75).
Reviewin adults with overweight/obesity
Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis · Diabetes, obesity & metabolism · 29 Sep 2026
Body weight
downin humans1High certainty
1 study
Body weight
downin humans1High certainty
Dual GLP-1/gcgr agonists decrease body weight in humans (MD: -6.65 kg).
Reviewin adults with overweight/obesity
Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis · Diabetes, obesity & metabolism · 29 Sep 2026
Associations
1Adverse events
upin humans1RR 1.16High certainty
1 study
Adverse events
upin humans1RR 1.16High certainty
Dual GLP-1/gcgr agonists raise the risk of adverse events in humans (RR: 1.16).
Reviewin adults with overweight/obesity
Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis · Diabetes, obesity & metabolism · 29 Sep 2026